Fusen Pharmaceutical Company Limited, an investment holding company, engages in the manufacturing and sale of pharmaceutical products in the People's Republic of China. The company offers Shuanghuanglian oral solutions and injections; Sanhuang tablet; heat-clearing and detoxicating oral solutions; Flunarizine hydrochloride capsules; Sanhuang tablets; compound ferrous sulfate granules; and other pharmaceutical products. It is also involved in manufacturing and sale of pharmaceutical package materials; research and development of pharmaceutical products; sale of construction materials and pharmaceutical products; and provision of business management and consulting services. Its medicines are used for the treatment of heat-clearing and detoxification, cardiovascular and cerebrovascular, antihypertensive and hypoglycemic, tonifying, qi-regulating, anti-anemia, and antibacterial and anti-inflammatory. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
Frequently asked questions
What sector does Fusen Pharmaceutical Company Ltd (1652) operate in?
Fusen Pharmaceutical Company Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Fusen Pharmaceutical Company Ltd (1652) current stock price?
As of the latest data, Fusen Pharmaceutical Company Ltd stock price is HK$0.80, with a previous close of HK$0.77. Fusen Pharmaceutical Company Ltd gained HK$0.03 in the last trading session, representing a 3.9% increase.
What is Fusen Pharmaceutical Company Ltd (1652) current market capitalization?
Fusen Pharmaceutical Company Ltd market cap is approximately 591.44 million.
What is Fusen Pharmaceutical Company Ltd (1652) EBITDA?
Fusen Pharmaceutical Company Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 4.49 million.
Does Fusen Pharmaceutical Company Ltd (1652) pay dividends?
No. Fusen Pharmaceutical Company Ltd does not pay a dividend.
What is Fusen Pharmaceutical Company Ltd (1652) beta (volatility) score?
Fusen Pharmaceutical Company Ltd has a beta of 0.243, indicating lower volatility than the overall market.
